40 YEARS OF COLLABORATING FOR A CURE

SAMUEL WAXMAN CANCER RESEARCH FOUNDATION
Now in its fortieth year, the Samuel Waxman Cancer Research Foundation (SWCRF) is an international nonprofit organization dedicated to curing and preventing cancer. SWCRF realizes its mission by funding cutting-edge research that identifies and corrects the abnormal gene function that causes cancer. This research is the basis for developing targeted, minimally toxic treatments for patients.

SWCRF pioneered the practice of collaboration among cancer investigators across the world’s top research institutes. This philosophy built a formidable scientific brain trust with a global reach—the Institute Without Walls. It augments the pace and impact of SWCRF-funded scientists’ projects through scientific exchange not previously practiced in the competitive world of research.

Looking to its next forty years, SWCRF will continue to be on the frontlines in the battle to eradicate cancer through its investments in leading-edge research by the brightest scientific minds around the globe. SWCRF has also launched The Partnership for Aging and Cancer Research, a groundbreaking collaboration with the National Cancer Institute (NCI) and National Institute on Aging (NIA) to investigate the abnormal gene function that makes cancer a disease of the aging process. Much of the SWCRF-funded research is applicable to this category and can lead to potential treatments that flatten the curve of cancer as we age.

To realize these aspirations, SWCRF seeks to develop financial resources in support of its next phase of programmatic expansion and institutional growth. SWCRF has launched Collaborating for a Cure: The Campaign for the Samuel Waxman Cancer Research Foundation. This five-year, $32 million campaign will provide the resources to sustain the level of excellence, integrity, and innovation that are the hallmark of SWCRF’s approach to funding cancer research. It will also secure SWCRF’s future as a financially sustainable, durable institution.
Dear Friends,

We are excited to announce that the Samuel Waxman Cancer Research Foundation is undertaking Collaborating for a Cure, a major capital campaign that will accelerate progress toward a cure for cancer and secure SWCRF’s sustainable future.

The Campaign is vital to funding SWCRF’s promising new initiatives, such as the SWCRF Partnership for Aging and Cancer Research, which has just been announced by the National Institutes of Health (NIH). This initiative brings together a public foundation with multiple government agencies within NIH to support cross-institutional and cross-disciplinary collaborative grants among scientists working in aging and cancer.

The Partnership will establish a template for pooling various scientific resources to address this long-underserved area of cancer investigation. The number of funding partnerships in this pioneering collaboration must grow in order to have the impact necessary to gain insight into the age-old question of why cancer is a disease of aging.

Without this research, we will be unable to significantly reduce cancer incidence and prevent its associated problems among the aging population. This research will also have a significant impact on our children and grandchildren since they will be at greater cancer risk due to a predicted longer lifespan.

Your gift to the Campaign will help drive the Partnership for Aging and Cancer Research, as well as sustain the level of excellence, integrity, and innovation that is the hallmark of the SWCRF approach to funding cancer research. It will also strengthen core operations, allowing SWCRF to continue to be a pace-setter in cancer research in the next forty years.

We hope you will lend your support to the Campaign.

With gratitude,

Samuel Waxman, M.D.  
Founder and CEO

William T. Sullivan  
Executive Director

Samuel Waxman, M.D.  
William T. Sullivan
Dear Friends,

As a Samuel Waxman Cancer Research Foundation (SWCRF) board member for over 20 years, I am deeply honored to serve as the Chair of Collaborating for A Cure: The Campaign for the Samuel Waxman Cancer Research Foundation.

All of us have been touched by cancer in some way. SWCRF has witnessed too many wonderful people of all ages and backgrounds be taken from their loved ones by this terrible disease. We've shared their stories at our annual Gala and stood by their families in tribute to their legacies as we joined with philanthropic leaders to advance research for a cure.

After 40 years of funding leading-edge research by the brightest minds in cancer research, we at SWCRF are gratified to see the landscape of research transformed by the model of collaboration pioneered by SWCRF in 1976. Exciting new cancer therapies are emerging more frequently these days, powered by advances in technology and the quickened pace of investigation facilitated by information sharing. The innovative theories of SWCRF-funded scientists are being applied to a wide range of cancer gene programming initiatives.

Our funded research has led to new clinical trials currently in process for potential treatments for blood malignancies, liver, lung, ovarian, breast, and pediatric cancer. For the patient receiving a lifesaving treatment, this investment is priceless.

With Campaign investments in programming and organizational infrastructure, SWCRF will fortify its role in bringing together the world’s top scientists to share knowledge that speeds the pace of progress in the quest for a cure.

Winning the war against cancer is one of the great medical crusades of the 21st century, and SWCRF will be on the front lines of this fight. On behalf of the Committee, we ask you to join us in collaborating for a cure.

Sincerely,

Michael Nierenberg
Chairman of the Board
Samuel Waxman Cancer Research Foundation
40th Anniversary Campaign, Chair
CONTINUED INVESTMENT IN RESEARCH CREATES MOMENTUM. SINCE 1976, EACH NEW YEAR LEADS TO ADVANCEMENTS. JOIN OUR COLLABORATION AND HELP US TO DEFEAT CANCER FASTER.

1976
An improved treatment for colon cancer.

1978
Leukemia cells are shown to differentiate (mature), the basis for differentiation therapy of cancer.

1982
SWCRF and Chinese investigators collaborate on landmark studies of leukemia differentiation therapy.

1986
The first of 14 conferences on differentiation therapy of cancer.

1988
Differentiation therapy with retinoic acid (RA) results in remission of Acute Promyelocytic Leukemia (APL).

1989
Breast cancer cells are shown to differentiate by targeted compounds.

1997
Arsenic trioxide (ATO) with RA treatment turns APL 90% curable.

2003
SWCRF Institute Without Walls is organized, which today includes 30 investigators.
2004
Mutations in certain lung cancers, the basis for targeted therapy.

2005
A molecular "switch" for dormancy permits cells to evade chemotherapy and seed metastasis.

2010
SWCRF reports new target for lymphoma therapy.

2011
Design of a therapy to block metastasis formation.

2013
First effective medical treatment for liver cancer.

2014
Identification of new targets for brain cancer therapy.

2015
Genomic classification of liver cancer.

2016
Combined epigenetic and immunotherapy for lung cancer.

2016
Development of a drug for a form of childhood leukemia.

2016
SWCRF celebrates 40 years and $90 million of research support.

2017
Launch of SWCRF Partnership for Aging and Cancer Research with NCI and NIA.
ancer is a disease of aging. As people are living longer and global populations are projected to increase dramatically, the incidence of cancer is expected to soar as well. The U.S. Census Bureau estimates that the population of people over 65 will reach 83.7 million in 2050, almost double its size of 43.1 million in 2012. According to NCI, cancer incidence increases significantly after age 40, and the median age of people diagnosed with cancer in the United States is 65. Americans diagnosed with the most prevalent cancer types are, on average, over the age of 50.

Despite the alarming rise in cancer incidence as we age, research that focuses on the intersection of cancer and aging is severely underfunded. The SWCRF Institute Without Walls is an international brain trust with global reach at the forefront of identifying and correcting cancer-causing abnormal gene function. We are positioned to lead a global effort to prevent the dramatic increased cancer incidence among people ages 40 and older. We have formed the Partnership for Aging and Cancer Research Program as a collaboration to lead the cancer research field toward possible breakthroughs that may speed new minimally toxic therapies to diminish this growing threat to the reward of increased longevity.

Your Campaign gift is an investment in speeding the pace of progress in the quest for a cancer cure and in SWCRF’s sustainable future.

The Campaign

SECUURING SWCRF’S FUTURE AS A DYNAMIC FORCE IN CANCER RESEARCH

The Campaign will provide the resources to sustain and grow the Institute Without Walls programming and invest in cutting-edge initiatives. It will leverage support for SWCRF’s signature programmatic initiative—Aging and Cancer—while positioning the Foundation to further strengthen our overall development program, thus ensuring future generations will continue to benefit from our pioneering research efforts.

THE CAMPAIGN WILL RAISE $32 MILLION IN SUPPORT OF FOUR CATEGORIES:

- Partnership for Aging and Cancer Research ($8.75 million)
- Institute Without Walls Programs ($17.8 million)
- Operations ($2.5 million)
- Endowment ($2.5 million)
Art work pages 1-16 from cellular biology series in watercolor and oil by Joel Filipe.
The SWCRF Partnership for Aging and Cancer Research Program will launch in 2018 as a two-year pilot program executed as a collaboration between SWCRF, NCI, and NIA. The Program, which will be administered by NCI, plans to award up to $3 million in its launch phase to teams of scientists working jointly in aging and cancer research, collaborating across NCI and NIA research facilities and independent academic research institutes. Research funded by the Program will address how aging affects cancer development and how scientists can use their deepening knowledge of aging to enhance prevention or treatment of cancer.

The goals of the SWCRF Partnership for Aging and Cancer Research Program are to identify the causal factors that contribute to the growing prevalence of cancer among people as they age and develop minimally toxic treatments to prevent this projected cancer epidemic. To further address this clinical need in cancer research SWCRF will seek additional partners to expand the program. Our long-term goal is to build a $20 million aging and cancer research funding program.
The SWCRF Institute Without Walls is a network that connects thirty research laboratories directed by the brightest scientific minds collaborating throughout North America, Asia, and Europe. By working together to share their most recent findings, our researchers speed the pace toward new breakthroughs. Since its inception, SWCRF has awarded approximately $100 million to support the work of more than two hundred researchers across the globe. SWCRF collaborators have leadership roles in science, business, and beyond, reflecting the SWCRF heritage of funding excellence in cancer research.

Looking ahead, the Campaign will enable SWCRF to invest in new ways to capitalize on its forty-year history of collaborative research by forging alliances with like-minded institutions in order to accelerate the development of novel diagnostic and therapeutic strategies for its Partnership for Aging and Cancer Research initiative.
collaborating for a cure
Operations

The Campaign will position SWCRF for programmatic and operational growth for the future. With strategic investments, SWCRF will have in place the kind of robust infrastructure, staffing, and enhanced capacity that reflect its growth and mirror the larger institution it will become.

Endowment

The Campaign will enable SWCRF to build an endowment and maintain itself as a financially stable institution. This will be the Foundation's first-ever invested endowment, and we plan to build it over the coming years to at least four times our operating budget.
Campaign Leadership

The Campaign is led by a dedicated, impassioned, and hard-working Development Committee, which will play an active role in stewarding the fundraising drive over the course of the Campaign period. This ten-member Committee has been constituted from SWCRF’s Board and is comprised of leading professionals who share a passion for and commitment to SWCRF’s mission:

James E. Frankel, Partner, Schiff Hardin LLP
Howard Kurz, Co-Founder, Lily Pond Capital Management
Paul J. Massey Jr., President, Investment Sales – Cushman & Wakefield
Michael Nierenberg, President and CEO, New Residential Investment Corporation and Managing Director, Fortress Investment Group
Lewis A. Rubin, Chief Operating Partner, Davis & Gilbert LLP
William T. Sullivan, Executive Director, Samuel Waxman Cancer Research Foundation
Samuel Waxman, M.D., Founder and CEO, Samuel Waxman Cancer Research Foundation
Spencer Waxman, Principal Executive Officer and Founder, Shannon River Partners
Dena K. Weiner, Vice President, SWCRF Board
Ari Zagdanski, Principal, Kinsman Property Group
Cancer Affects Us All

JOIN OUR COLLABORATION TO SUPPORT RESEARCH FOR A CURE

With your Campaign gift, SWCRF will be able to continue to invest in innovative research that might not otherwise receive funding, such as the Partnership for Aging and Cancer Research, our new initiative with NCI to fund collaborative research on the causes and effects of aging that drive the increased incidence of cancer. Partnership-funded investigations help pave the way toward new therapeutic strategies that improve the quality of life for people living longer with cancer. They can also lead to the development of minimally toxic therapies that benefit all cancer patients.

Your support is crucial.

CREDITS:
Campaign Consultant: Koszyn & Company
Design Direction: Ron Gabriel
Cover Photo: Hal Gatewood
Inside Photos: Joel Filipe (http://joelfilipe.com)
Headshots Pages 2-3: Jerry Lacay
Project Management: Edgar Trinidad, SWCRF

SWCRF logo:
The SWCRF cell icon symbolizes the Foundation’s breakthrough cure for a deadly leukemia through differentiation of the cancer cell.